Skip to main content
. 2023 Sep 27;14:1194090. doi: 10.3389/fpsyt.2023.1194090

Figure 5.

Figure 5

Comparison of the proportion of responders (Rs) in CADOT with the literature. The first reference (gray vertical band) is our lead-in period of 24 weeks during which four patients remitted with other treatment than DATA (but three remitted with bupropion + SSRI, i.e., a dopaminergic strategy). The second is the proportion of Rs when combining stages 3 and 4 of the STAR*D trial (38–40). Regarding monoamine oxidase inhibitors (MAOI), the results in non-stratified treatment-resistant depression (TRD) were extracted from (41). MAOI in atypical depression: weighted average of Rs from an intention-to-treat perspective (see references in text). Proportion of TRD and bipolar depressions (BPD) are indicated on the right. MAOI in anergic depression: weighted average of Rs from an intention-to-treat perspective. All studies are from the Pittsburgh group (see references in text). The single dopamine D2 receptor agonist (D2RAG) on which we have sufficient data is pramipexol (PPX). The proportion of Rs with PPX in TRD is recomputed from 10 studies reviewed in reference (42).